Advanced searches left 3/3

Methyl - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 20 June 2022

* If you want to update the article please login/register

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

"If perampanel blocks the ability of ketamine to improve the clinical and neural signatures of major depression, it would indicate that AMPAR stimulation is crucial for human anti-depressant effects of ketamine. " The purpose of this research is to determine whether or not stimulation of Alpha-Amino-3-Methyl-4-Isoxazole Propionic Acid receptors is important to ketamine's anti-depressant response. Specifically, we will investigate the following hypotheses: During ketamine infusion in people with treatment-resistant depression, we will witness the following hypotheses: Perampanel pre-treatment decreases ketamine-related rises in prefrontal functional connectivity and CMRO2 in individuals with treatment-resistant depression. Pre-treatment with Perampanel reduces ketamine-induced rises in prefrontal CMRO2 and functional connectivity, which were observed at 24 hours in individuals with treatment-resistant depression. The Hamilton Depression Inventory, a 24-hour survey conducted by Perampanel, shows that ketamine's positive effect on clinical improvement was reduced by a dosage of 24-hours in people with treatment-resistant depression. Prefrontal functional connectivity and CMRO2 changes during ketamine infusion and 24 hours post-infusion are correlated with clinical improvement, according to the Hamilton Depression Inventory in individuals with treatment-resistant depression. The investigators have included a small out-of-scanner investigation to see the effectiveness of the ketamine/perampanel mixture in human subjects as this is the first, to the investigator's knowledge, to use ketamine and perampanel. This registration focuses on the main study that will accompany the safety investigation and determine the effect of perampanel and ketamine on people with treatment-resistant depression.

Source link: https://clinicaltrials.gov/ct2/show/NCT03367533

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions